6 July 2022 - New immunoglobulin treatment offers Canadian patients option of subcutaneous once-monthly (every three or four weeks) dosing. ...
1 June 2022 - Designation is based on XTEND-1 Phase 3 study data demonstrating a clinically meaningful prevention of bleeds and ...
1 April 2022 - Newly available treatments can help Canadians living with haemophilia A better manage their bleeding episodes ...
27 February 2022 - GC Pharma today announced that it has received a complete response letter from the U.S. FDA in ...
31 January 2022 - Vonvendi [von Willebrand factor (recombinant)] is the first and only treatment approved for routine prophylaxis to reduce ...
7 December 2021 - Families, providers can utilise flexible infusion schedule to meet patient needs. ...
30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease. ...
12 August 2021 - GreenGene F now approved in China, provides more haemophilia A patients access to proven therapy. ...
3 August 2021 - CSL Behring has received U.S. FDA approval for its supplemental request for co-packaging of a convenience ...
20 July 2021 - FDA approval based on positive results of international, multi-center ProDERM study. ...
28 June 2021 - Catalyst Biosciences today announced the U.S. FDA has granted fast track designation for Marzeptacog alfa (activated), MarzAA, ...
4 June 2021 - Today, the U.S. FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type ...
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...
12 May 2021 - The TGA has deemed it to be a new biological entity. Others will beg to differ. ...
5 May 2021 - A significant milestone towards entering the world's largest plasma product marketplace. ...